Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients Ardelyx, Inc. , a clinical-stage biopharmaceutical business centered on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. As previously reported, at the 50 mg dose of tenapanor, the study met its main efficacy endpoint of a rise in the entire spontaneous bowel motion responder rate. Most secondary endpoints, including abdominal pain and other IBS-C and abdominal symptoms, demonstrated meaningful improvements clinically.What’s amoxicillin prescribed for typically? Most commonly it really is prescribed for respiratory system infections and top respiratory attacks such as rhinosinusitis, otitis mass media and lower respiratory tract infections . How did your research into the effectiveness of amoxicillin originate? Various things after that came together – the mix of funds being obtainable through the European Commission, and a group of like-minded European researchers ranging from microbiologists, geneticists to primary care physicians came to put in the grant bid together.